Paxlovid (nirmatrelvir/ritonavir) can be used in dialysis patients, but it requires significant dose reductions and careful monitoring because the kidneys are the primary route for clearing one of its active ingredients. The standard dose was never designed for people with little or no kidney function, and early pharmacokinetic studies show that drug levels in dialysis patients can climb to many times what is needed, even at reduced doses. A growing body of small studies and case series suggests that with the right adjustments, the drug still works and appears reasonably safe in this population, though the evidence base remains far thinner than for patients with normal kidneys.
Why Kidney Function Changes Everything About Paxlovid Dosing
Nirmatrelvir, the component of Paxlovid that directly blocks the virus’s ability to replicate, depends heavily on the kidneys to leave the body. In a pharmacokinetic study comparing people across a range of kidney function, those with severe impairment had roughly three times the overall drug exposure compared to people with normal kidneys. Peak blood levels were about 50 percent higher, but total exposure over time was the real concern: the drug simply lingered much longer when the kidneys could not clear it efficiently. Renal clearance in people with moderate impairment dropped by about 47 percent, and in severe impairment it dropped by 80 percent.1PubMed Central. Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal Impairment
Based on those findings, the approved labeling already includes a dose reduction for people with moderate kidney impairment: instead of 300 mg of nirmatrelvir twice daily, the recommended dose drops to 150 mg twice daily, paired with the same 100 mg of ritonavir. The ritonavir dose stays the same because its job is to slow the liver’s breakdown of nirmatrelvir; it is not itself cleared primarily by the kidneys.2PubMed Central. A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir But dialysis patients sit beyond “severe impairment” on the spectrum. Their kidneys contribute essentially nothing to drug clearance, which means even the reduced dose may be too much.
What Dialysis Actually Does to Nirmatrelvir Levels
Hemodialysis does pull some nirmatrelvir out of the blood, but not as much as you might hope. One study measured nirmatrelvir concentrations before and after a four-hour hemodialysis session and found levels fell by about 42 percent during dialysis. Even after that drop, trough concentrations remained roughly ten times above the level needed to suppress the virus in lab studies.3PubMed Central. Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with Hemodialysis Another research group reported that hemodialysis removes up to about 31 percent of unbound nirmatrelvir. When they measured blood levels a full day after the last dose in hemodialysis patients receiving a quarter of the standard dose, the minimum concentration was still nearly eight times above the upper end of the effective concentration range seen in lab tests.4PubMed Central. Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
The practical takeaway is that dialysis sessions help, but they do not normalize drug levels the way they do for some other medications. The drug accumulates between sessions, and a standard or even halved dose can result in sustained exposure well beyond what is therapeutically necessary. That excess exposure does not automatically mean toxicity, but it does raise the stakes for side effects and creates a situation where clinicians are essentially flying without a well-validated dosing map.
How Clinicians Are Adjusting Doses
Because the product label does not include a specific recommendation for dialysis patients, several research groups have experimented with different regimens. One approach that has appeared in published pilot data is 150 mg of nirmatrelvir with 100 mg of ritonavir given once daily for five days, rather than twice daily.5PubMed. A pilot study on Paxlovid therapy for hemodialysis patients with severe acute respiratory syndrome coronavirus 2 infections That is essentially one-quarter of the standard daily dose. In that pilot study involving six treated patients and seven controls, no serious adverse reactions were recorded, and none of the treated patients progressed to more severe disease, while four control patients did.
Other groups have tried a half-dose regimen (150 mg nirmatrelvir twice daily) with a supplemental half-dose after dialysis to compensate for drug removal during the session. Even at these reduced doses, blood levels remained comfortably above the concentration needed to inhibit the virus.6PubMed Central. Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19 The trouble is that most of these dosing strategies have been tested in handfuls of patients. No large randomized trial has compared different regimens head to head in people on dialysis, so the “best” dose is still a matter of clinical judgment informed by drug-level monitoring when available.
A case series of four hemodialysis patients who received nirmatrelvir/ritonavir with dose adjustments found that symptoms improved around three days after starting treatment and viral load dropped after about ten days. Nausea and vomiting were the main side effects, but the drug was generally tolerated.7PubMed Central. Nirmatrelvir/ritonavir use in patients with COVID-19 on hemodialysis: a case series These are encouraging results, but four patients is about as small as a study can get.
Does Paxlovid Actually Help People with Very Low Kidney Function?
The largest dataset on this question comes from a study of over 4,000 patients whose kidney filtration rate fell between 15 and 30, meaning advanced but not yet dialysis-dependent impairment. Among those treated with nirmatrelvir/ritonavir, the risk of acute respiratory failure was cut roughly in half, and pneumonia risk dropped by about 40 percent compared to untreated patients. The treatment did not appear to increase the risk of heart failure, liver injury, or further kidney damage.8American Journal of Kidney Diseases. Safety and Effectiveness of Nirmatrelvir-Ritonavir in Patients With Advanced Kidney Dysfunction and COVID-19
That study is reassuring because the fear with dialysis patients has always been twofold: that the drug accumulates to harmful levels, and that even if it does not cause direct harm, the immune and metabolic complexities of kidney failure might blunt its effectiveness. The respiratory failure and pneumonia findings suggest the drug is still doing its job in people with severely compromised kidneys. But the study population was not exclusively on dialysis, so the results should be taken as suggestive rather than definitive for that specific group.
Paxlovid Versus Molnupiravir in Advanced Kidney Disease
Molnupiravir is the other oral antiviral available for COVID-19, and because it is not cleared by the kidneys in the same way, it has sometimes been seen as the “easier” choice for people with kidney disease. But a large retrospective study comparing the two drugs in patients with advanced kidney disease found that nirmatrelvir/ritonavir outperformed molnupiravir on the outcomes that matter most. Over 90 days, nirmatrelvir/ritonavir was associated with lower rates of death and hospitalization compared to molnupiravir. Rates of ICU admission, need for a ventilator, liver injury, stroke, and heart attack were similar between the two drugs.9The Lancet Regional Health – Western Pacific. Comparison of safety and efficacy between Nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infection in patients with advanced kidney disease: a retrospective observational study
The mortality advantage was not trivial. The absolute risk reduction at 90 days was about 3 percentage points, and the relative risk of death was roughly 38 percent lower with nirmatrelvir/ritonavir. For hospitalization, the absolute risk reduction was about 4 percentage points.10The Lancet Regional Health – Western Pacific. Comparison of safety and efficacy between Nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infection in patients with advanced kidney disease: a retrospective observational study This does not mean molnupiravir is useless. For patients who genuinely cannot tolerate Paxlovid or who take medications that interact dangerously with ritonavir, molnupiravir remains a reasonable fallback. But the data suggest that if the drug interaction and dosing hurdles of Paxlovid can be managed, it is the more effective option even in this challenging population.
The Transplant Problem
A large share of dialysis patients arrived at kidney failure through a transplant that eventually failed, and many others are waiting for one or living with a functioning graft that is declining. Kidney transplant recipients take immunosuppressive drugs, and this is where Paxlovid’s second ingredient creates serious trouble. Ritonavir is a potent inhibitor of the liver enzyme system responsible for breaking down tacrolimus, cyclosporine, sirolimus, and everolimus. When ritonavir blocks that enzyme, blood levels of these immunosuppressants can spike dramatically, sometimes rising anywhere from about two to twenty times their normal concentration.11American Journal of Kidney Diseases. Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection
The consequences of that spike are not theoretical. A published case report describes a kidney transplant patient who developed an abruptly high tacrolimus level after starting Paxlovid, leading to significant symptoms, treatment interruption, and acute kidney injury to the transplanted organ.12PubMed Central. Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report Tacrolimus has an extremely narrow therapeutic window. Too little and the immune system attacks the graft. Too much and the drug itself poisons the kidneys, the brain, or both. The interaction with ritonavir pushes levels far above the safe range in a matter of hours.
Transplant teams who do prescribe Paxlovid in this setting typically hold tacrolimus entirely for the duration of treatment or reduce it to a fraction of the usual dose, checking blood levels daily or every other day. The process requires close coordination between infectious disease specialists, nephrologists, and transplant pharmacists. For patients on dialysis who also take immunosuppressants for a failing or recently failed graft, the layered complexity of dose-adjusting both Paxlovid and the immunosuppressant simultaneously makes this one of the more challenging drug-management scenarios in clinical medicine.13American Journal of Kidney Diseases. Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection
Side Effects and Tolerability
For dialysis patients without the transplant complication, the most commonly reported side effects mirror what is seen in the general population: a metallic or bitter taste (sometimes described as so unpleasant that patients want to stop treatment), nausea, and vomiting. In the small case series and pilot studies published so far, these side effects have generally been manageable and have not led to treatment discontinuation in most patients.14PubMed Central. Nirmatrelvir/ritonavir use in patients with COVID-19 on hemodialysis: a case series
The safety concern unique to this population is accumulation-driven toxicity. Because the drug clears so slowly, side effects that might be transient in someone with normal kidneys could persist or intensify. The studies that have measured drug levels in dialysis patients consistently find concentrations well above what is needed for antiviral activity, which means patients are essentially getting more drug than intended throughout their treatment course. Whether that excess leads to problems beyond gastrointestinal discomfort is still an open question, largely because the total number of dialysis patients studied remains small. The large observational study in people with advanced kidney dysfunction did not find increased rates of heart failure, liver injury, or acute kidney injury with treatment, which is reassuring.15American Journal of Kidney Diseases. Safety and Effectiveness of Nirmatrelvir-Ritonavir in Patients With Advanced Kidney Dysfunction and COVID-19
Other Drug Interactions Beyond Immunosuppressants
Ritonavir does not only interact with transplant drugs. It inhibits the same liver enzyme that metabolizes a long list of common medications, and dialysis patients often take many of them. Certain blood pressure medications, cholesterol-lowering statins, blood thinners, anti-seizure drugs, and sedatives can all be affected. The ritonavir component was originally developed as an HIV protease inhibitor and is used in Paxlovid specifically because it slows down the liver’s processing of nirmatrelvir, keeping nirmatrelvir in the bloodstream longer. That same mechanism raises levels of many other drugs a patient might be taking.
For dialysis patients, who typically take a median of ten or more daily medications, the interaction-checking step before starting Paxlovid is not trivial. Some drug combinations are absolute contraindications, meaning Paxlovid simply cannot be given. Others require temporary dose adjustments or brief pauses. The challenge is compounded by the fact that Paxlovid treatment lasts only five days, but ritonavir’s enzyme-blocking effect can linger for a few days after the last dose, meaning the interaction window extends beyond the treatment period itself.
Timing Paxlovid Around Dialysis Sessions
One practical question that comes up for patients and their care teams is whether to take Paxlovid before or after a dialysis session, and whether the dialysis schedule should be adjusted during the five-day treatment course. Since dialysis removes a meaningful fraction of nirmatrelvir from the blood, some protocols call for giving a supplemental dose after each session to replace what was removed. The research group that tested reduced doses in hemodialysis patients administered half of the research dose after dialysis for exactly this reason.16PubMed Central. Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
The logic is straightforward: if a four-hour dialysis session drops drug levels by 40 percent or so, and the patient’s kidneys are not going to clear any additional drug between sessions, post-dialysis dosing helps maintain effective concentrations without the drug climbing to extreme levels between runs. But this adds yet another variable to an already complicated regimen. Most dialysis patients receive treatment three times a week, meaning some days involve a Paxlovid dose, then dialysis, then another dose, while other days involve Paxlovid alone with no dialysis to draw drug levels down.
Peritoneal Dialysis
Nearly all the published pharmacokinetic and clinical data on Paxlovid in dialysis involve hemodialysis, which uses a machine to filter blood through an external circuit. Peritoneal dialysis, the other major form, works differently. It uses the lining of the abdomen as a filter and is typically done at home, either continuously throughout the day or overnight. Because peritoneal dialysis is a gentler, slower process than hemodialysis, it likely removes less nirmatrelvir per session. There is almost no published data on nirmatrelvir clearance during peritoneal dialysis specifically, which means clinicians managing these patients are extrapolating from hemodialysis data and general pharmacokinetic principles. If you are on peritoneal dialysis and prescribed Paxlovid, the dose adjustment should be at least as aggressive as for hemodialysis patients, and blood-level monitoring, where available, becomes even more important.
When Therapeutic Drug Monitoring Matters
For most people who take Paxlovid, nobody checks drug levels. The standard five-day course produces predictable blood concentrations in people with normal or moderately impaired kidneys, so monitoring is unnecessary. Dialysis changes that equation. Multiple studies have used blood-level measurements to demonstrate that even reduced doses produce nirmatrelvir concentrations far above the effective threshold.17PubMed Central. Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with Hemodialysis In research settings, these measurements guide dose adjustments in real time. In everyday clinical practice, therapeutic drug monitoring for nirmatrelvir is not widely available because most hospital labs are not set up to run the assay quickly enough to be useful during a five-day treatment course.
This gap between what researchers can do and what frontline clinicians can do is one of the biggest obstacles to optimizing Paxlovid use in dialysis patients. Without routine access to drug-level testing, prescribers rely on population-level dosing recommendations derived from small studies, combined with close clinical monitoring for side effects. If you are on dialysis and your medical team does have access to nirmatrelvir assays, it is worth asking whether blood levels will be checked. If they do not have access, that does not mean Paxlovid should be avoided, but it does mean your team will be relying on published dosing strategies rather than real-time fine-tuning.
Why the Evidence Is Still So Thin
Dialysis patients are routinely excluded from the pivotal clinical trials that lead to drug approvals. The original trials that established Paxlovid’s efficacy excluded people with severe kidney impairment, largely because of the dosing uncertainty and safety concerns described above. This is a common pattern in drug development: the patients who most need a medication are often the last to get rigorous evidence supporting its use. Kidney failure makes COVID-19 substantially more dangerous. Dialysis patients who contract the virus face higher rates of hospitalization, intensive care, and death than the general population. So the clinical need is acute, and the evidence, while growing, is still built mostly from pharmacokinetic modeling, small pilot studies, and retrospective observational data rather than the gold standard of large randomized trials.
The current evidence is moving in a consistent direction. Drug levels, even at reduced doses, remain well above what is needed to fight the virus. Small studies and case series show clinical benefit. The largest observational study in advanced kidney disease found meaningful reductions in respiratory complications without increased organ damage. And head-to-head comparisons with the alternative oral antiviral suggest Paxlovid remains the stronger option when it can be safely managed.18The Lancet Regional Health – Western Pacific. Comparison of safety and efficacy between Nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infection in patients with advanced kidney disease: a retrospective observational study What is missing is the kind of large, controlled trial that would settle the dosing question and provide firm safety numbers for the dialysis-specific population. Until that trial happens, prescribing Paxlovid to dialysis patients will remain a carefully managed balancing act between the drug’s clear antiviral benefit and the pharmacokinetic reality of using it in people whose bodies handle it very differently than intended.